Discover opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Jan 14, 2025 to Jan 14, 2025
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Cincinnati Acquisition Division (CAD) | Inotiv Inc | Jan 14, 2025 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS
Effective Date
Jul 15, 2024
Expires
Effective: Jul 15, 2024
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS
ActiveINVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. SEPTEMBER 3, 2024 TO MARCH 2, 2026. N01DA-23-8935
Effective Date
Sep 12, 2024
Expires
INVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. SEPTEMBER 3, 2024 TO MARCH 2, 2026. N01DA-23-8935
ActiveINVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. POP: 5/2/2025 - 11/1/2026. N01DA-23-8935
Effective Date
May 2, 2025
Expires
INVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. POP: 5/2/2025 - 11/1/2026. N01DA-23-8935
ActiveNON-GLP 3-STRAIN AMES ASSAY
Effective Date
Apr 7, 2025
Expires
Effective: Apr 7, 2025
NON-GLP 3-STRAIN AMES ASSAY
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis